IL-2 as adjuvant for vaccination with cells malignantly converted by HPV 16 or 3-MC

International Journal of Oncology

Volumn 8, Issue 3, 1996, Pages 477-481

  Bubeník, Jan ^a   Símová, Jana ^a   Vondrys, Pavel ^a   Vonka, Richard ^b   Kitasato, Hidero ^b   Bostík, Pavel ^b   Vonka, Vladimír ^b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Cancer immunotherapy; Cell vaccines; Human papilloma virus; Interleukin 2; MC induced sarcomas

Indexed keywords

CANCER VACCINE; RECOMBINANT INTERLEUKIN 2; TUMOR REJECTION ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HAMSTER; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS ONCOGENE;

EID: 0030002458     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.8.3.477     Document Type: Article

References (34)

1. Wu T-C: Immunology of the human papilloma virus in relation to cancer. Curr Opinion Immunol 6: 746-754, 1994.
2. Brandsma JL: Animal models for HPV vaccine development. Papillomavirus Rep 5: 105-112, 1994.
3. Vonka V: Human papillomavirus vaccines. Folia Biol (Praha), (In press).
4. Bubeník J: Cytokine-modified vaccines in the therapy of cancer. Pharmacol Ther (In press).
5. Bystryn JC, Henn M, Li J and Shroba S: Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 52: 5948-5953, 1992.
6. Lanzavecchia A: Identifying strategies for immune intervention. Science 260: 937-944, 1993.
7. Tindle RW and Crawford L: Immune responses to human papillomaviruses and the prospects for human papillomavirus specific immunization. Curr Top Microbiol Immunol 186: 217-253, 1994.
8. Heath AW and Playfair JHL: Cytokines as immunological adjuvants. Vaccine 10: 427-434, 1992.
9. Bubeník J: Utilization of IL-2 and IL-2 gene transfer for regional immunotherapy of cancer. In: Cytokine-induced Tumor Immunogenicity. From exogenous molecules to gene therapy. Forni G, Foa R, Santoni A and Frati L (eds) London, Academic Press, pp113-130, 1994.
10. McCune CS: Exogenous cytokines enhance tumor specific responses to vaccines. In: Cytokine-induced Tumor Immunogenicity. From exogenous molecules to gene therapy. Forni G, Foa R, Santoni A and Frati L (eds) London, Academic Press, pp87-96, 1994.
11. Bubeník J: Cytokine gene-modified vaccines for immunotherapy of cancer. Int J Oncol 6: 45-49, 1995.
12. Mitchell MS, Harel W, Kempf RA: Active specific immunotherapy for melanoma. J Clin Oncol 8: 856-869, 1990.
13. McGee MC, Lytle GL, Malnar KF, Price JA and Humphrey LJ: Melanoma tumor vaccine: five year follow up. J Surg Oncol 47: 233-238, 1991.
14. Bystryn JC, Oratz R, Roses D, Harris M, Henn M and Lew R: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69: 1157-1164, 1992.
15. Meneguzzi G, Cerni C, Kieny MP and Lathe R: Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181: 62-69, 1991.
16. Chen L, Mizuno MT, Singhal MC, Hu S-L, Galloway DA, Hellström J and Hellström KE: Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148: 2617-2621, 1992.
17. Kast WM, Brandt RMP, Drijfhout JW and Melief CJM: Human leukocyte antigen - A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 14: 115-120, 1993.
18. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJM and Kast WM: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249, 1993.
19. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, Ras E, van den Burg SH, ter Schegget J, Melief CJM and Kast WM: Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 25: 2638-2642, 1995.
20. Ossevoort MA, Feltkamp MCW, van Veen KJH, Melief CJM and Kast WA: Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 18: 86-90, 1995.
21. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M, Oseroff C, Grey HM, Melief CJM and Kast WM: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154: 5934-5943, 1995.
22. Bubeník J, Indrová M, Nemecková S, Malkovsky M, von Broen B and Anderlíková J: Solubilized tumour-associated antigens of methylcholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph node cells, macrophage electrophoretic mobility assay and transplantation tests. Int J Cancer 21: 348-355, 1978.
23. Karasuyama H and Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2,3,4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97-104, 1988.
24. Bubeník J, Perlmann P, Indrová M, Símová J, Jandlová T and Neuwirt J: Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containg preparations. Cancer Immunol Immunother 14: 205-206, 1983.
25. Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J and Toulcová A: Tumour inhibitory effects of TCGF/IL-2/ containing preparations. Cancer Immunol Immunother 19: 57-61, 1985.
26. zur Hausen H: Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 122: 3-13, 1996.
27. Nunberg JH, Doyle MV, York SM and York CJ: Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 86: 4240-4343, 1989.
28. Reddy DN, Reddy PG, Xue W, Minocha HC, Daley MJ and Blecha F: Immunopotentiation of bovine respiratory disease virus vaccines by interleukin 1-β and interleukin-2. Vet Immunol Immunopath 37: 25-38, 1993.
29. Nash AD, Lofthouse SA, Barcham GJ, Jacobs HJ, Ashman K, Meeusen ENT, Brandon MR and Andrews AE: Recombinant cytokines as immunological adjuvants. Immunol Cell Biol 71: 367-379, 1993.
30. Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Maizel A and Wanebo HJ: Anti-tumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 4: 1121-1127, 1994.
31. Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA and Restifo NP: IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 154: 5282-5292, 1995.
32. zur Hausen H: Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 184: 9-13, 1991.
33. Vousden KH, Donniger J, DiPaolo JA and Lowy DR: The E7 open reading frame of human papillomavirus type 16 encodes a transforming gene. Oncogene Res 3: 167-175, 1988.
34. Shih C and Weinberg RA: Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161-169, 1982.